| Literature DB >> 34944076 |
Emily Lazarus1, Paola Bermudez-Lekerika2,3, Daniel Farchione4,5, Taylor Schofield5, Sloan Howard5, Iskender Mambetkadyrov5, Mikkael Lamoca5, Iris V Rivero1,5, Benjamin Gantenbein2,3, Christopher L Lewis6, Karin Wuertz-Kozak5,7.
Abstract
Hydrogels are commonly used for the 3D culture of musculoskeletal cells. Sulfated hydrogels, which have seen a growing interest over the past years, provide a microenvironment that help maintain the phenotype of chondrocytes and chondrocyte-like cells and can be used for sustained delivery of growth factors and other drugs. Sulfated hydrogels are hence valuable tools to improve cartilage and intervertebral disc tissue engineering. To further advance the utilization of these hydrogels, we identify and summarize the current knowledge about different sulfated hydrogels, highlight their beneficial effects in cartilage and disc research, and review the biofabrication processes most suitable to secure best quality assurance through deposition fidelity, repeatability, and attainment of biocompatible morphologies.Entities:
Keywords: chondrogenic phenotype; chondroitin sulfate; heparan sulfate; sulfated alginate; sulfated hyaluronan; sustained release of growth factors
Mesh:
Substances:
Year: 2021 PMID: 34944076 PMCID: PMC8700363 DOI: 10.3390/cells10123568
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600
Sulfated hydrogels for sustained release of growth factors.
| Biomaterial | Cell Type | Growth Factor | Release | Ref |
|---|---|---|---|---|
| Sulfated Alginate Hydrogels | ||||
| Alginate sulfate | Chondrocytes | FGF2 | • Almost 40% of FGF2 retained after two weeks compared to the almost 20% retained by the controls | [ |
| Sulfated Hyaluronan Hydrogels | ||||
| Sulfated hyaluronan | Keratinocytes and dermal fibroblasts | EGF | • Prolonged release of EGF when studied over three days | [ |
| Sulfated HEMA-HA | N/A | SDF-1α | • Prolonged release when studied over twelve days | [ |
|
LS-MeHA and | Human MSCs | TGF-β1 | • Has extended release of TGF-β1 | [ |
| Chondroitin Sulfate Hydrogels | ||||
| Chitosan-based microspheres (CMs) into CMC-OCS hydrogels | Chondrocytes | BSA | • Lowest release rate of BSA over two weeks | [ |
Abbreviations: BSA, Bovine Serum Albumin; Human MSCs, Human Mesenchymal Stem Cells; TGF-β1, Transforming Growth Factor-β1; SDF-1α, Stromal Cell-Derived Factor-1α; EGF, Epidermal Growth Factor; FGF2, Fibroblast Growth Factor; HEMA-HA, Hydroxyethyl Methacrylate Hyaluronic Acid.
Sulfated hydrogels for cartilage and IVD supporting phenotype with relevant gene expressions and cell responses.
| Biomaterial | Cell type | Gene Expression(s) | Cell Response(s) | Ref |
|---|---|---|---|---|
| Chondroitin Sulfate Hydrogels | ||||
| Catechol-functionalized chondroitin sulfate | Human | • Collagen type II and SOX9 ⬆ (compared to pellet culture) | • Good cell viability | [ |
| Chondroitin | Human | • Collagen type II and aggrecan ⬆ | • GAG and collagen deposition ⬆ | [ |
| CMP-TA/CS-TA | Porcine auricular chondrocytes | • Collagen type I ⬇ | • Cell viability and proliferation ⬆ | [ |
| PNIPAAm-g-CS | Human embryonic kidney 293 cells | • Low cytotoxicity | [ | |
| Bovine NP disc-derived self-assembled ECM functionalized with chondroitin sulfate | Porcine | • GAG/collagen ratio synthesis ⬆‡ | [ | |
| Heparin-based Hydrogels | ||||
| Heparan sulfate- | Human | • Collagen type II and aggrecan ⬆ | • Homogeneous distribution of collagen type I & II deposition | [ |
| HRP-crosslinked Hep-TA/Dex-TA | Bovine chondrocytes | • Collagen type II ⬆ | • Cell viability ⬆ | [ |
| Gelatin incorporated PLCL scaffold with Hep-SH | Rabbit articular cartilage chondrocytes | • Collagen type II ⬆ in vitro and | • GAG deposition ⬆ | [ |
| Sulfated Alginate Hydrogels | ||||
| Calcium-crosslinked sulfated alginate | Calf cartilage chondrocytes | • COL1A2/COL2A1 ratio ⬆‡ | • Cell proliferation ⬆† | [ |
| Barium-crosslinked sulfated alginate | Bovine articular cartilage chondrocytes | • FGFR2 ⬇‡ | • Cellular recognition/adhesion ⬆† | [ |
| Tyrosinase-crosslinked alginate sulfate tyramine | Human and bovine articular cartilage chondrocytes | • Collagen type II ⬆‡ | • Good cell viability | [ |
| Sulfated Hyaluronan Hydrogels | ||||
| HA-pNIPAM | Bovine NP | • Collagen type I ⬇ | • NP phenotype ⬆ | [ |
| Sulfated HA | hMSCs | • Collagen type II ⬆ | • Sulfation has no effect on cell viability | [ |
Abbreviations: ADSCs, adipose-derived mesenchymal stem cells; CMP-TA, carboxymethyl pullulan tyramine; CS-TA, chondroitin sulfate-tyramine; Dex-TA, dextran–tyramine; ECM, extracellular membrane; GAG, Glycosaminoglycan; HA, Hyaluronanic acid; Has2, hyaluronan synthase 2; Hep-SH, Thiol derivative of heparin; Hep-TA, heparin–tyramine; HRP, horseradish peroxidase; MSCs, mesenchymal stem cells; NP, nucleus pulposus; Sef, similar expression to FGF genes; PG, proteoglycan; PLCL, poly(L-lactide-co-ε-caprolactone); PNIPAAm-g-CS, poly(N-isopropylacrylamide)-graft-chondroitin sulfate; pNIPAM, poly(N-isopropyl acrylamide); SOX9, SRY-Box transcription factor 9. † Compared with lower sulfation ‡ Compared to cells grown in a monolayer. “↑” means upregulation and ”↓” means down-regulation.
Figure 1Schematic of the biofabrication process of sulfated hydrogels.